David R. Margrave - Jul 15, 2024 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
Chief Financial Officer
Signature
/s/ David R. Margrave
Stock symbol
LTRN
Transactions as of
Jul 15, 2024
Transactions value $
$0
Form type
4
Date filed
7/17/2024, 04:30 PM
Previous filing
Nov 2, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LTRN Stock Option (Right to Buy) Award $0 +52K $0.00 52K Jul 15, 2024 Common Stock 52K $4.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024.